Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Ajovy (Fremanezumab-Vfrm) is a prescription injectable medication used for the preventive treatment of migraine in adults and pediatric patients aged 12 years and older (weighing at least 45 kg). It belongs to a class of drugs called CGRP inhibitors (calcitonin gene-related peptide inhibitors). Ajovy is manufactured by Teva Pharmaceuticals and was designed specifically to reduce the number of migraine days per month — it is not used to treat a migraine attack that has already started.
Ajovy is self-administered as a subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. Patients can choose between monthly or quarterly dosing, making it one of the more flexible options among injectable CGRP preventive treatments.
Ajovy is a humanized monoclonal antibody that targets and binds to calcitonin gene-related peptide (CGRP), a protein that plays a central role in triggering migraine attacks. By neutralizing CGRP before it can bind to its receptor, Ajovy effectively blocks a key step in the migraine cascade.
Unlike older preventive migraine medications (like topiramate or beta-blockers) that were originally developed for other conditions, Ajovy was purpose-built to target the migraine pathway. This means it tends to have fewer systemic side effects and a more targeted mechanism of action.
Ajovy can be dosed as 225 mg once monthly or 675 mg once quarterly (three 225 mg injections given at the same time at different injection sites). Both dosing schedules are equally effective — your doctor will help you choose based on your preference.
Ajovy is a specialty biologic that is primarily distributed through specialty pharmacies rather than standard retail pharmacies. As of early 2026, Ajovy is not listed on the FDA or ASHP drug shortage lists, which is good news. However, because it's a specialty injectable medication, availability can vary by location and pharmacy network. Some patients have reported intermittent delays when filling or refilling prescriptions, particularly through certain specialty pharmacy channels.
If your usual specialty pharmacy doesn't have it in stock, ask your neurologist's office for help — they often have relationships with multiple specialty pharmacy networks and can route your prescription to one with current availability.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Because most insurance plans require prior authorization and step therapy documentation, it's often easiest to get Ajovy prescribed through a neurologist who is familiar with the approval process.
No, Ajovy is not a controlled substance. It has no DEA scheduling and carries no risk of abuse or dependence. It can be prescribed with standard refills and does not require the special prescribing restrictions associated with controlled medications.
Ajovy has a relatively favorable side effect profile compared to older migraine preventives. The most commonly reported issues are local injection site reactions, which are typically mild and resolve on their own. Serious side effects are rare but can include hypersensitivity reactions such as rash, hives, and in very rare cases, anaphylaxis or angioedema (swelling of face, tongue, or throat). Seek immediate medical attention if you experience signs of a severe allergic reaction.
All four alternatives target the same CGRP pathway. The main differences are route of administration (injection vs. IV vs. oral) and dosing frequency. If you prefer not to inject yourself, Qulipta offers a daily oral option, while Vyepti is administered as a quarterly IV infusion at a doctor's office.
Ajovy has no known clinically significant drug interactions. As a monoclonal antibody, it is not metabolized by the liver's cytochrome P450 enzyme system, which is responsible for most drug-drug interactions. This makes Ajovy particularly easy to add to existing medication regimens.
That said, always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you're taking. While there are no formal contraindications with other drugs, your doctor should be aware of your full medication list to provide the best care.
Ajovy is a well-established, purpose-built migraine prevention treatment that offers patients the flexibility of monthly or quarterly dosing. With no generic or biosimilar currently available, the cash price remains high at $690–$1,019 per month — but Teva's savings card can bring the cost down to as low as $0–$15 for commercially insured patients, and the Teva Cares Foundation provides free medication for eligible uninsured or underinsured individuals.
While Ajovy is generally available through specialty pharmacies, it's not something you'll find on the shelf at your local CVS or Walgreens. Work with your neurologist's office and your insurance plan's preferred specialty pharmacy to ensure a smooth prescription fill. If you're having trouble finding Ajovy in stock, Medfinder can help you locate availability near you.
%2C%20Color%3DOriginal.png)
